Oruka Therapeutics (ORKA)
NASDAQ:ORKA
Want to see ORKA full AI Analyst Report?
Top Page
Oruka Therapeutics
(NASDAQ:ORKA)
Select Model
Select Model
Rating:58Neutral
Price Target:
$65.00
▼(-5.69% Downside)
Action:ReiteratedDate:05/02/26
The score is mainly constrained by pre-revenue financials with widening losses and rising cash burn, partly offset by a strong, low-debt balance sheet. Technicals are moderately supportive with a longer-term uptrend but mixed near-term momentum. A negative P/E and no dividend limit valuation support, while strong Phase 2a trial results provide a notable positive catalyst.
Positive Factors
Compelling Phase 2a efficacy
The Phase 2a EVERLAST-A results (PASI100 63.5% vs 4.8% placebo) materially raise the probability of later‑stage success and clinical differentiation. Durable high efficacy versus peers supports stronger positioning, partnership interest, and a clearer go‑to‑market case if confirmed in Phase 2b/3.
Negative Factors
Pre-revenue development stage
Oruka is pre‑revenue, so intrinsic value depends entirely on clinical and regulatory outcomes. Until commercialization, there's no internal cash generation to de‑risk programs; commercial execution (launch, pricing, uptake) remains unproven and extends time to sustainable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Compelling Phase 2a efficacy
The Phase 2a EVERLAST-A results (PASI100 63.5% vs 4.8% placebo) materially raise the probability of later‑stage success and clinical differentiation. Durable high efficacy versus peers supports stronger positioning, partnership interest, and a clearer go‑to‑market case if confirmed in Phase 2b/3.
Read all positive factors
Oruka Therapeutics (ORKA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.75B
Dividend YieldN/A
Average Volume (3M)530.53K
Price to Earnings (P/E)―
Beta (1Y)1.19
Revenue GrowthN/A
EPS Growth63.93%
CountryUS
Employees28
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.31
Shares Outstanding59,856,915
10 Day Avg. Volume602,310
30 Day Avg. Volume530,527
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)2.93
Price to Sales (P/S)0.00
P/FCF Ratio-15.64
Enterprise Value/Market Cap0.65
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-87.28K
Enterprise Value/Ebitda-22.18
Forecast
1Y Price Target
$128.50Price Target Upside86.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-2.26
Revenue Forecast (FY)N/A
Oruka Therapeutics Business Overview & Revenue Model
Company Description
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA....
How the Company Makes Money
As a clinical-stage biotechnology company, Oruka Therapeutics does not have publicly available evidence of recurring product revenue from marketed therapies; as such, revenue from commercial drug sales is null. The company primarily funds operatio...
Oruka Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
74
Positive
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -83.00K | -27.00K | -114.00K | -91.00K | -93.00K |
| EBITDA | -121.97M | -82.23M | -9.81M | -19.23M | -9.64M |
| Net Income | -105.43M | -83.72M | -9.93M | -19.32M | -9.74M |
Balance Sheet | |||||
| Total Assets | 488.62M | 396.02M | 43.09M | 54.92M | 50.43M |
| Cash, Cash Equivalents and Short-Term Investments | 337.04M | 375.65M | 42.45M | 53.36M | 49.07M |
| Total Debt | 1.93M | 968.00K | 383.00K | 483.00K | 450.00K |
| Total Liabilities | 16.69M | 13.80M | 1.41M | 3.88M | 3.91M |
| Stockholders Equity | 471.93M | 382.22M | 41.67M | 51.04M | 46.52M |
Cash Flow | |||||
| Free Cash Flow | -88.42M | -58.03M | -10.91M | -18.80M | -7.74M |
| Operating Cash Flow | -88.21M | -57.84M | -10.91M | -18.76M | -7.72M |
| Investing Cash Flow | -96.75M | -330.13M | -2.00K | -43.00K | -19.00K |
| Financing Cash Flow | 170.31M | 449.54M | 0.00 | 23.09M | 48.45M |
Oruka Therapeutics Technical Analysis
Positive
68.92
Price Trends
42.38
Positive
36.72
Positive
27.88
Positive
Market Momentum
7.65
Negative
78.18
Negative
90.89
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORKA, the sentiment is Positive. The current price of 68.92 is above the 20-day moving average (MA) of 54.23, above the 50-day MA of 42.38, and above the 200-day MA of 27.88, indicating a bullish trend. The MACD of 7.65 indicates Negative momentum. The RSI at 78.18 is Negative, neither overbought nor oversold. The STOCH value of 90.89 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ORKA.
Oruka Therapeutics Risk Analysis
Oruka Therapeutics disclosed 1 risk factors in its most recent earnings report. Oruka Therapeutics reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Oruka Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $1.42B | -6.67 | -32.49% | ― | ― | -101.89% | |
58 Neutral | $3.75B | -13.11 | -25.30% | ― | ― | 63.93% | |
58 Neutral | $1.94B | 4.53 | 1813.84% | ― | 157.01% | 94.31% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $513.00M | -2.55 | -1849.88% | ― | 209.14% | 11.31% | |
47 Neutral | $1.25B | -13.39 | -42.90% | ― | ― | 13.36% | |
46 Neutral | $352.97M | -12.74 | -43.61% | ― | -100.00% | -20.71% |
* Healthcare Sector Average
ORKA
Oruka Therapeutics
66.46
56.48
565.93%
VSTM
Verastem
5.95
-1.06
-15.12%
ANAB
AnaptysBio
69.78
55.96
405.03%
CMPX
Compass Therapeutics
1.94
0.08
4.30%
OLMA
Olema Pharmaceuticals
14.63
9.07
163.13%
BCAX
Bicara Therapeutics Inc.
22.72
8.72
62.29%
Oruka Therapeutics Corporate Events
Financial DisclosuresPrivate Placements and Financing
Oruka Therapeutics Completes Public Equity Offering Under Shelf
Neutral
Apr 30, 2026
On April 28, 2026, Oruka Therapeutics entered into an underwriting agreement with a syndicate of investment banks to offer 9,660,000 shares of common stock at $72.50 per share, including a 30‑day option for underwriters to buy up to 1,449,00...
Business Operations and StrategyProduct-Related Announcements
Oruka Therapeutics Reports Strong Phase 2 Psoriasis Results
Positive
Apr 27, 2026
On April 27, 2026, Oruka Therapeutics reported positive interim results from its Phase 2a EVERLAST-A trial of ORKA-001 in moderate-to-severe plaque psoriasis, with 63.5% of treated patients achieving complete skin clearance (PASI 100 and identical...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.